Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Acute Low Back Pain
Interventions: Combination drug (Acetaminophen + Tramadol), Placebo; Drug
Lead sponsor: Labopharm Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Montgomery, Alabama • Centennial, Colorado • Hialeah, Florida + 14 more

Conditions: Iron Overload
Interventions: Not listed
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 2 Years to 25 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: Relatlimab, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • San Luis Obispo, California + 17 more

Conditions: Post-Operative Pain, Total Knee Arthroplasty
Interventions: Total knee arthroplasty (TKA), Cryoablation; Procedure · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Hamstring Tightness
Interventions: Dry needling, Sham needling, Blunt needle placement, Standard hamstring stretching exercise; Procedure · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Photosensitive Epilepsy
Interventions: Fenfluramine Hydrochloride; Drug
Lead sponsor: Elizabeth Anne Thiele; Other
Eligibility: 4 Years to 25 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amphetamine Dependence
Interventions: Mirtazapine, Placebo; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Colorectal Cancer
Interventions: celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 2,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 826
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 536 more

Conditions: Therapy, Exercise
Interventions: Isometric exercises, Eccentric exercises; Other
Lead sponsor: Carrick Institute for Graduate Studies; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cape Canaveral, Florida

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Duarte, California • Atlanta, Georgia • Lexington, Kentucky + 6 more

Conditions: Familial Amyotrophic Lateral Sclerosis
Interventions: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days; Drug
Lead sponsor: Edward Kasaraskis; Other
Eligibility: 20 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Seasonal Influenza Preventative Vaccine Pharmacodynamics
Interventions: VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large); Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Opioid-related Disorders
Interventions: Buprenorphine, Morphine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Medication Adherence, Hypertension
Interventions: My Interprofessional Care team for Adherence and Research Engagement (MI-CARE); Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Hemophilia A
Interventions: Moroctocog alfa (AF-CC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months to 15 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 7
States / cities: Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Neurofibromatosis 2, Vestibular Schwannoma
Interventions: Lapatinib; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 4 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Prostate Cancer
Interventions: Pelvic DCFPyL PET-MRI fusion or PET/MRI; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stem Cell Transplantation
Interventions: Auto-hMSCs, Allo-hMSCs; Biological
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 90 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Miami, Florida • Baltimore, Maryland

Conditions: Diabetic Peripheral Neuropathy
Interventions: Mazisotine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more

Conditions: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL); Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dyslipidemia
Interventions: JTT-302, Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Healthy
Interventions: Single-Dose IV Oritavancin Diphosphate and Warfarin, Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Liver Transplant
Interventions: Immunosuppression Reduction; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 13 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Obstructive Sleep Apnea of Adult
Interventions: Verily Sleep Apnea (VSA) Program/App; Device
Lead sponsor: Verily Life Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: South San Francisco, California

Search by objective public record fields.

A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID Versus Placebo for the Treatment of Acute Low Back Pain

Changes in Pituitary Iron and Volume With Deferasirox

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

The Benefits Of Cryoablation In Patients Undergoing Total Knee Arthroplasty

Hamstring Tightness

Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).

Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Changes in Attention Level Due to Isometric Exercises and Level Three Progression Eccentric Movements

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Buprenorphine's Dose Response Curve

My Interprofessional Care Team for Adherence and Research Engagement Disparities

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects

Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation

Baseline Sleep Apnea Study #2